

## **Curriculum Vitae Dr Michael Shalmi**

Academic degree: Dr. med. University in Copenhagen

Occupation: Consultant and Investor

Place of residence: Hellerup, Denmark

### **Personal data**

Year of birth: 1965

Nationality: Danish

### **Member of the Supervisory Board of Evotec SE**

First appointed on 14 June 2017

Last elected at the Annual General Meeting on 14 June 2017 until the Annual General Meeting, which will decide on the approval of the members of the Supervisory Board for fiscal year 2018

### **Education**

2000 Scandinavian International Management Institute

Master of Business Administration

1991 University in Copenhagen

Conferral of a doctorate (Dr. med.)

1984 – 1991 University in Copenhagen

Study of medicine

### **Professional career**

Since March 2019 Consulting firm ACMS

Consultant and Investor

2017 – 2019 Novo Holdings A/S

Managing Director, Head of Principal Investments

2009 – 2016 Novo Holdings A/S

Various positions, most recently Head of Large Investments

1994 – 2009

Novo Nordisk A/S

Various positions, most recently Vice President, Global Development, Clinical Operations Management

**Appointments to other statutory supervisory boards and comparable national and international supervisory bodies of commercial enterprises**

Synlab Ltd. (Member of the Board of Directors)

and to bodies of the following companies and investments of Novo Group:

Momentum Gruppen A/S (Member of the Board of Directors)

ERT HoldCo A/S (Member of the Board of Directors)

Xellia HoldCo A/S (Member of the Board of Directors)

Novo Invest 1 A/S (Member of the Board of Directors)

ENV HoldCo A/S (Member of the Board of Directors)

Sonion HoldCo A/S (Member of the Board of Directors)

In addition, he has been nominated as candidate and Chairman of the Board of Directors of Active Biotech AB.

**Other significant activities besides the Supervisory Board mandate**

n/a

**Relevant knowledge, skills and experience**

Dr Michael Shalmi (born in 1965, Danish citizen) was appointed Member of the Supervisory Board on 14 June 2017 for a term of two years. His current term will expire at the end of the AGM held in the year 2019. Since March 2019, Dr Michael Shalmi has been pursuing his personal consulting firm ACMS. From January 2017 to February 2019, Dr Shalmi served as Managing Director, Head of Principal Investments of Novo Holdings A/S. From 2009 to 2016, he served as Senior Partner at Novo Holdings A/S where he led at first the division Novo Growth Equity and then for two years the division Large Investments. In this role, he was responsible for the strategic long-term investments in life science. Prior to his career at Novo Holdings A/S, he spent 15 years at Novo Nordisk A/S where he held a number of different international management positions in research, clinical development as well as marketing and management, lastly as Vice President, Global Development, Clinical Operations Management. Prior to working at Novo Nordisk, he was research associate at the universities in Copenhagen and Manchester.

During his career, Dr Michael Shalmi gained extensive expertise in medicine and especially focused on drug and product development and on the development of commercialisation strategies. Dr Shalmi holds further positions as a member of other statutory supervisory boards such as Member of the Supervisory Board of Synlab Ltd., Momentum Gruppen A/S, ERT HoldCo A/S, ENV HoldCo A/S, Xellia HoldCo A/S, Novo Invest 1 A/S, and Sonion HoldCo A/S.

Dr Shalmi received his Doctorate of Medicine from the University in Copenhagen and his MBA degree from the Scandinavian International Management Institute.

Due to his extensive knowledge of various aspects in the Pharma industry as well as his excellent expertise in pre-clinical as well as in clinical discovery and development combined with his focus on strategy and investment, Dr Shalmi ideally the future Supervisory Board of Evotec SE.

**Personal or business relationships in accordance with section 5.4.1 paragraphs 6 to 8 of the German Corporate Governance Code**

In the opinion of the Supervisory Board, Dr Michael Shalmi and Evotec SE, its affiliates, the bodies of Evotec SE or a significant shareholder in Evotec SE, have no personal or business relationships that an objective judging shareholder would consider authoritative for their voting decision. Shareholders who directly or indirectly hold more than 10% of the Company's voting shares are considered as significant shareholders.